Inflammation-associated lysyl oxidase protein expression in vivo, and modulation by FGF-2 plus IGF-1.
Lysyl oxidase is the extracellular enzyme that catalyzes oxidative deamination of peptidyl-lysine residues in elastin precursors, and lysine and hydroxylysine residues in collagen precursors to form peptidyl-aldehydes. These aldehydes then spontaneously condense to crosslink collagen and elastin and thereby allow the formation of a mature and functional extracellular matrix. In the present study, cryosections made from aseptic immune-induced periapical lesions experimentally generated in laboratory rats were examined by immunohistochemistry to investigate whether lysyl oxidase protein expression is altered in inflamed oral tissues. Periapical lesions are experimentally induced endodontic lesions of tooth roots. In addition, the effect of administration of a mixture of fibroblast growth factor (FGF)-2 and insulin-like growth factor (IGF)-1 into these lesions on lysyl oxidase expression was determined. Lysyl oxidase expression was found to be increased in non-mineralized connective tissue adjacent to inflamed lesions. Morphometric analyses indicated that maximum lysyl oxidase expression occurred at a discrete distance from the lesion not exceeding 350 microm from the inflammatory cells. Staining was associated with mesenchymal cells with a fibroblastic morphology. No lysyl oxidase staining was found near teeth where no lesion was induced. Application of a mixture of FGF-2 and IGF-1 resulted in a further twofold increase in lysyl oxidase expression. These results provide a new in vivo model to study lysyl oxidase regulation, and suggest that inflammatory cells may control lysyl oxidase expression in oral tissues, possibly by a mechanism involving secretion of cytokines and other factors, probably contributing to the regulation of extracellular matrix accumulation.
Trackman
P C
PC
Division of Oral Biology, Boston University Medical Center, MA 02118, USA. trackman@acs.bu.edu
Graham
R J
RJ
Bittner
H K
HK
Carnes
D L
DL
Gilles
J A
JA
Graves
D T
DT
D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008297:Male; D010485:Periapical Periodontitis / Q000201:enzymology* / Q000276:immunology; D010486:Periapical Tissue / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology; D008249:Protein-Lysine 6-Oxidase / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D008249:Protein-Lysine 6-Oxidase